TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24084539

Group type: EXPERIMENTAL
Intervention: Mifepristone followed by misoprostol (800 micrograms vaginally followed by 400 micrograms orally every 3 hours, max 4 doses)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Mifepristone followed by oxytocin (high-concentration drip, max 150 milli-international units/min for up to 36 hours)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Mifepristone followed by misoprostol
Number of subjects: 142

Group type: COMPARATOR
Intervention: Mifepristone followed by oxytocin
Number of subjects: 142
Study: 21122577

Group type: EXPERIMENTAL
Intervention: 20mg prednisone daily for two weeks prior to surveillance colonoscopy
Number of subjects: 60

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 60
Study: 18478482

Group type: EXPERIMENTAL
Intervention: Accelerated perioperative care and rehabilitation intervention
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control group (current perioperative procedure)
Number of subjects: 87
Study: 16009737

Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 12705111

Group type: EXPERIMENTAL
Intervention: Hydration management intervention (fluid intake goal based on weight)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Hydration management intervention (with > or = 90% compliance)
Number of subjects: 98
Study: 10832986

Group type: EXPERIMENTAL
Intervention: Operated eyes (LASIK)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control eyes (unoperated)
Number of subjects: 28
Study: 8877677

Group type: EXPERIMENTAL
Intervention: Atorvastatin capsules (0.5 to 120 mg)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Atorvastatin solution (0.5 to 120 mg)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 2005249

Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 64
Study: 6361837

Group type: EXPERIMENTAL
Intervention: Relaxation Training (RT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Exercise Training only
Number of subjects: 0
Study: 30693746

Group type: EXPERIMENTAL
Intervention: Single-incision robotic cholecystectomy (SIRC)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Conventional laparoscopic cholecystectomy (CLC)
Number of subjects: 121
Study: 28415931

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 80

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study: 25112662

Group type: COMPARATOR
Intervention: CRT-D with BIV pacing <90%
Number of subjects: 1219

Group type: COMPARATOR
Intervention: CRT-D with BIV pacing 91-96%
Number of subjects: 1219

Group type: COMPARATOR
Intervention: CRT-D with BIV pacing >97%
Number of subjects: 1219

Group type: EXPERIMENTAL
Intervention: Every 1 percentage point increase in BIV pacing within CRT-D group
Number of subjects: 1219

Group type: EXPERIMENTAL
Intervention: Increasing BIV pacing percentage
Number of subjects: 1219
Study: 24214189

Group type: EXPERIMENTAL
Intervention: Topiroxostat 60 mg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Topiroxostat 180 mg
Number of subjects: 48

Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 21061131

Group type: EXPERIMENTAL
Intervention: Glucamesh®
Number of subjects: 50

Group type: COMPARATOR
Intervention: Prolène®
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study: 19638921

Group type: EXPERIMENTAL
Intervention: Laparoscopic Roux-en-Y gastric bypass (LRYGB)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Laparoscopic sleeve gastrectomy (LSG)
Number of subjects: 27
Study: 18003554

Group type: EXPERIMENTAL
Intervention: Subthalamic nucleus (STN) stimulation
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: L-dopa administration
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Combination of STN stimulation and L-dopa
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 30
Study: 15476989

Group type: EXPERIMENTAL
Intervention: Health education strategy (written booklet on health problems)
Number of subjects: 687

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 687
Study: 11022827

Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg daily for 3 weeks
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 31
Study: 9002496

Group type: EXPERIMENTAL
Intervention: Acadesine (0.1 mg·kg‐1·min‐1; intravenous infusion for 7 continuous hours and via the cardioplegia solution)
Number of subjects: 4043

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4043

Group type: EXPERIMENTAL
Intervention: Acadesine
Number of subjects: 4043
Study: 8455236

Group type: EXPERIMENTAL
Intervention: Single intravesical instillation of 80 mg epirubicin
Number of subjects: 431

Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 431
Study: 2937434

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 50

Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 50
Study: 30679293

Group type: EXPERIMENTAL
Intervention: internet-delivered cognitive-behavioural therapy (internet-CBT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: waitlist control
Number of subjects: 100
Study: 28610945

Group type: EXPERIMENTAL
Intervention: Intensive intervention group (IG)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Conventional group (CG)
Number of subjects: 150
Study: 26703280

Group type: EXPERIMENTAL
Intervention: Phenylephrine 1.0%-ketorolac 0.3%
Number of subjects: 808

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 808
Study: 23522518

Group type: EXPERIMENTAL
Intervention: Communication with caregivers at a fourth-grade level on the Flesch-Kincaid scale.
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Increased use of passive sentences in communication.
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Caregiver understanding and comfort with administering pain medications.
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Caregiver quality of life.
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Grade level of talk with caregivers and hospice teams.
Number of subjects: 47
Study: 21338818

Group type: EXPERIMENTAL
Intervention: Artificial mothering (15 min of vigorous physical and verbal stimulation conducted within 1 to 2h of birth and repeated 1 to 2h later)
Number of subjects: 41

Group type: COMPARATOR
Intervention: No tactile or verbal stimulation other than that required for feeding (group 1)
Number of subjects: 41
Study: 19493281

Group type: EXPERIMENTAL
Intervention: Victimization through sexual coercion by the husband (measured via CTS-2)
Number of subjects: 460

Group type: EXPERIMENTAL
Intervention: Higher conflict levels
Number of subjects: 460

Group type: EXPERIMENTAL
Intervention: Low self-control and high violent socialization
Number of subjects: 460
Study: 17912364

Group type: COMPARATOR
Intervention: 0% CO2
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 9% CO2
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 17.5% CO2
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 35% CO2
Number of subjects: 64
Study: 15447897

Group type: EXPERIMENTAL
Intervention: Iron (20 mg)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Zinc (20 mg)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Iron+Zinc
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Micronutrient mix (MM) of 16 vitamins and minerals including iron and zinc
Number of subjects: 221

Group type: COMPARATOR
Intervention: Riboflavin
Number of subjects: 221
Study: 11723368

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 536
Study: 9917449

Group type: EXPERIMENTAL
Intervention: Home-based management
Number of subjects: 63

Group type: COMPARATOR
Intervention: Hospital-based group (control)
Number of subjects: 63
Study: 7479418

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low dose warfarin
Number of subjects: 0
Study: 2156538

Group type: EXPERIMENTAL
Intervention: hydrocortisone‐17‐alpha‐butyrate eardrops
Number of subjects: 46

Group type: COMPARATOR
Intervention: oxytetracycline/hydrocortisone with polymyxin B (TPB)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: both treatments
Number of subjects: 46
Study: 6107056

Group type: COMPARATOR
Intervention: Nitrous oxide continued after operation (20 patients)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Nitrous oxide discontinued immediately after operation (30 patients)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Flunitrazepam with nitrous oxide (24 patients)
Number of subjects: 74
Study: 31686302

Group type: EXPERIMENTAL
Intervention: video‐recorded social contact
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: audio/visual simulation
Number of subjects: 244

Group type: COMPARATOR
Intervention: no intervention
Number of subjects: 244
Study: 31116166

Group type: EXPERIMENTAL
Intervention: Ocular Surface Disease Index (OSDI) vision subscale
Number of subjects: 487

Group type: EXPERIMENTAL
Intervention: Severe meibomian gland plugging
Number of subjects: 487

Group type: EXPERIMENTAL
Intervention: Obstructed meibomian glands
Number of subjects: 487

Group type: EXPERIMENTAL
Intervention: Tear breakup time (TBUT) >5 seconds
Number of subjects: 487
Study: 29193711

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 226
Study: 26218934

Group type: EXPERIMENTAL
Intervention: Parasagital approach
Number of subjects: 56

Group type: COMPARATOR
Intervention: Midline approach
Number of subjects: 56
Study: 22801961

Group type: EXPERIMENTAL
Intervention: Lintuzumab (600 mg) plus low-dose cytarabine (20 mg subcutaneously twice daily)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Placebo plus low-dose cytarabine (20 mg subcutaneously twice daily)
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Lintuzumab (600 mg)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 211
Study: 22189801

Group type: EXPERIMENTAL
Intervention: Nutritional intervention (dietetic supplement during dialysis containing 355 kcal)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Nutritional intervention
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control Group (no intervention during the first three months)
Number of subjects: 18
Study: 19573869

Group type: EXPERIMENTAL
Intervention: Electrocautery incision (EI)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Savary bougienage (SB)
Number of subjects: 62
Study: 17123156

Group type: EXPERIMENTAL
Intervention: Explanation of comparison questions in the pretest interview
Number of subjects: 65

Group type: COMPARATOR
Intervention: No explanation of comparison questions
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Re-discussing comparison questions between charts
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Subjective stress ratings due to relevant and comparison questions
Number of subjects: 65
Study: 14645939

Group type: EXPERIMENTAL
Intervention: Tobacco use cessation and prevention interventions based on social influences and peer leader models.
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 44
Study: 10852998

Group type: EXPERIMENTAL
Intervention: Colonoscopy
Number of subjects: 973

Group type: COMPARATOR
Intervention: Barium enema
Number of subjects: 973
Study: 8850177

Group type: EXPERIMENTAL
Intervention: 0.65 g of n‐3 PUFA for 12 weeks
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 1378116

Group type: EXPERIMENTAL
Intervention: 100 mg ibopamine
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 6689676

Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nifedipine 30 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nifedipine 40 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 3763299

Group type: EXPERIMENTAL
Intervention: Breathing stuffed bear
Number of subjects: 0

Group type: COMPARATOR
Intervention: No breathing bear (Control)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No bear (Control)
Number of subjects: 0
Study: 30142795

Group type: EXPERIMENTAL
Intervention: Electro-acupuncture (EA)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Sham electro-acupuncture (sham-EA)
Number of subjects: 68
Study: 27358643

Group type: EXPERIMENTAL
Intervention: Intrathecal 2 mg midazolam
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intrathecal 20 micrograms fentanyl
Number of subjects: 40
Study: 24642345

Group type: EXPERIMENTAL
Intervention: Modafinil 400mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: COMPARATOR
Intervention: Healthy participants
Number of subjects: 30
Study: 22546748

Group type: EXPERIMENTAL
Intervention: Decision-training aid (written and graphical descriptions of expert consensus standard)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Control group (instructions to continue with the task)
Number of subjects: 165
Study: 21073703

Group type: EXPERIMENTAL
Intervention: Additional physiotherapy and occupational therapy services on Saturday
Number of subjects: 712

Group type: COMPARATOR
Intervention: Usual care physiotherapy and occupational therapy from Monday to Friday
Number of subjects: 712
Study: 19260323

Group type: EXPERIMENTAL
Intervention: Puerarin with aspirin
Number of subjects: 45

Group type: COMPARATOR
Intervention: Basic treatment
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (healthy persons)
Number of subjects: 45
Study: 15870588

Group type: EXPERIMENTAL
Intervention: Polestriding exercise training (24-week program, 3 times weekly)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Nonexercise attention control group
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Polestriding exercise training
Number of subjects: 49
Study: 14750378

Group type: EXPERIMENTAL
Intervention: Extracapsular cataract extraction (ECCE)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Phacoemulsification (PEA)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: ECCE
Number of subjects: 60
Study: 10825304

Group type: EXPERIMENTAL
Intervention: Beta-blockers (esmolol infusions on the day of surgery and metoprolol for the next 48 hours)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Control (no beta-blockers)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Control
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 107
Study: 9003980

Group type: EXPERIMENTAL
Intervention: Weak (1 micro Tesla), burst-firing magnetic fields applied for 20 min over the right temporoparietal lobe
Number of subjects: 0

Group type: COMPARATOR
Intervention: Weak (1 micro Tesla), burst-firing magnetic fields applied for 20 min over the left temporoparietal lobe
Number of subjects: 0

Group type: COMPARATOR
Intervention: Weak (1 micro Tesla), burst-firing magnetic fields applied for 20 min over both hemispheres
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 0
Study: 1614196

Group type: EXPERIMENTAL
Intervention: Desmopressin (0.3 microgram/kg)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study: 6367018

Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow graft with high dose cyclophosphamide and total body irradiation (8 Gray)
Number of subjects: 20
Study: 31407421

Group type: EXPERIMENTAL
Intervention: Early jaw exercise intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Late jaw exercise intervention
Number of subjects: 0
Study: 30335070

Group type: EXPERIMENTAL
Intervention: 20 mg of cortexin
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: 10 mg of cortexin
Number of subjects: 189

Group type: COMPARATOR
Intervention: Basic treatment only
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Laboratory data
Number of subjects: 189
Study: 28091501

Group type: EXPERIMENTAL
Intervention: Rac-hopantenic acid (pantogam activ) at a daily dose of 1200 mg for 21 days
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard therapy with SSRI antidepressants
Number of subjects: 50
Study: 25476698

Group type: EXPERIMENTAL
Intervention: Acupuncture (daily for nine consecutive days on five points, six cycles for a total of 60 days)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (wearing single-vision corrective lenses)
Number of subjects: 100
Study: 22036632

Group type: EXPERIMENTAL
Intervention: Laser peripheral iridotomy
Number of subjects: 734

Group type: COMPARATOR
Intervention: Control (fellow eye)
Number of subjects: 734
Study: 20538079

Group type: EXPERIMENTAL
Intervention: Intravenous Cefazolin
Number of subjects: 450

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 450
Study: 17928265

Group type: EXPERIMENTAL
Intervention: Get Moving advertisements
Number of subjects: 31

Group type: COMPARATOR
Intervention: Standard advertisements (Control)
Number of subjects: 31
Study: 16447355

Group type: EXPERIMENTAL
Intervention: Standard face-to-face MDT meetings
Number of subjects: 45

Group type: COMPARATOR
Intervention: Telemedicine-delivered MDT meetings
Number of subjects: 45
Study: 12578932

Group type: EXPERIMENTAL
Intervention: Ideomotor apraxia severity based on scores from a verbal gesture-to-command (pantomime) task
Number of subjects: 20

Group type: COMPARATOR
Intervention: Matched control subjects
Number of subjects: 20
Study: 10812737

Group type: EXPERIMENTAL
Intervention: ICCE with ACIOL
Number of subjects: 2000

Group type: COMPARATOR
Intervention: ICCE with aphakic spectacles (Control)
Number of subjects: 2000
Study: 8783774

Group type: EXPERIMENTAL
Intervention: Remikiren 600 mg orally for 8 days
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Remikiren 600 mg with hydrochlorothiazide 12.5 mg or 25 mg for last 4 days
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Remikiren 600 mg orally
Number of subjects: 29
Study: 1629891

Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methyldopa
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6148867

Group type: EXPERIMENTAL
Intervention: Propranolol with cimetidine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Propranolol alone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nadolol with cimetidine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Nadolol alone
Number of subjects: 12
Study: 31257623

Group type: EXPERIMENTAL
Intervention: Tact-Intraverbal (TI) group
Number of subjects: 32

Group type: COMPARATOR
Intervention: Intraverbal-Tact (IT) group
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 32
Study: 30284586

Group type: EXPERIMENTAL
Intervention: 2 mg hydromorphone (2 mL)
Number of subjects: 50

Group type: COMPARATOR
Intervention: 2 mL normal saline intravenously
Number of subjects: 50
Study: 26581682

Group type: EXPERIMENTAL
Intervention: Cocoa beverage containing 320 mg total cocoa flavanols/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cocoa beverage and Placebo beverage
Number of subjects: 0
Study: 25876348

Group type: EXPERIMENTAL
Intervention: Moving cupping therapy combined with autohemotherapy with acupoint injection (1 mL at each acupoint, once every 3 days)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Cetirizine tablets (10 mg once daily) and compound dexamethasone acetate cream (once to twice daily)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Moving cupping therapy combined with autohemotherapy with acupoint injection
Number of subjects: 104

Group type: COMPARATOR
Intervention: Cetirizine tablets and compound dexamethasone acetate cream
Number of subjects: 104
Study: 22466023

Group type: EXPERIMENTAL
Intervention: brief internet chat introduction
Number of subjects: 60

Group type: COMPARATOR
Intervention: control internet surfing condition
Number of subjects: 60
Study: 20140214

Group type: EXPERIMENTAL
Intervention: 10 microg FMP2.1 in 0.1 mL AS02(A)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 25 microg FMP2.1 in 0.25 mL AS02(A)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 50 microg FMP2.1 in 0.5 mL AS02(A)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Rabies vaccine (RabAvert)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: All malaria vaccine groups
Number of subjects: 100
Study: 18997466

Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine mouthrinse
Number of subjects: 14

Group type: COMPARATOR
Intervention: saline (control)
Number of subjects: 14
Study: 15824543

Group type: EXPERIMENTAL
Intervention: Case-parent triad approach
Number of subjects: 0

Group type: COMPARATOR
Intervention: Case-control approach
Number of subjects: 0
Study: 12478216

Group type: EXPERIMENTAL
Intervention: Alcohol (0.80 g/kg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Triazolam (0.25 mg/70 kg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 10048112

Group type: EXPERIMENTAL
Intervention: Multiple-tailored intervention
Number of subjects: 843

Group type: EXPERIMENTAL
Intervention: Single-tailored intervention
Number of subjects: 843

Group type: EXPERIMENTAL
Intervention: Standardized self-help guide
Number of subjects: 843

Group type: COMPARATOR
Intervention: No-information control group
Number of subjects: 843

Group type: EXPERIMENTAL
Intervention: Self-help materials (all types)
Number of subjects: 843
Study: 7497163

Group type: EXPERIMENTAL
Intervention: Regular invitation to mammographic screening for breast cancer
Number of subjects: 19844

Group type: COMPARATOR
Intervention: Unscreened control group
Number of subjects: 19844
Study: 1970633

Group type: EXPERIMENTAL
Intervention: 1 g DS implant
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (PL) implants
Number of subjects: 12
Study: 393242

Group type: EXPERIMENTAL
Intervention: Transdermal therapeutic system scopolamine (TTS-scopolamine)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Oral dimenhydrinate
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35